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Abstract
Background: Brain white matter hyperintensities (WMHs) commonly observed on brain imaging of older adults are
associated with balance and gait impairment and have also been linked to cognitive deficits. Parkinson’s disease (PD) is
traditionally sub-classified into the postural instability gait difficulty (PIGD) sub-type, and the tremor dominant (TD) sub-
type. Considering the known association between WMHs and axial symptoms like gait disturbances and postural instability,
one can hypothesize that WMHs might contribute to the disparate clinical sub-types of patients with PD.
Methods: 110 patients with PD underwent a clinical evaluation and a 3T MRI exam. Based on the Unified Parkinson Disease
Rating Scale, the patients were classified into motor sub-types, i.e., TD or PIGD, and scores reflecting PIGD and TD symptoms
were computed. We compared white matter burden using three previously validated methods: one using a semi-
quantitative visual rating scale in specific brain regions and two automated methods.
Results: Overall, MRI data were obtained in 104 patients. The mean WMHs scores and the percent of subjects with lesions in
specific brain regions were similar in the two subtypes, p=0.678. The PIGD and the TD scores did not differ even when
comparing patients with a relatively high burden of WMHs to patients with a relatively low burden. Across most of the brain
regions, mild to moderate correlations between WMHs and age were found (r=0.23 to 0.41; p,0.021). Conversely, no
significant correlations were found between WMHs and the PIGD score or disease duration. In addition, depressive
symptoms and cerebro-vascular risk factors were similar among the two subtypes.
Conclusions: In contrast to what has been reported previously among older adults, the present study could not
demonstrate any association between WMHs and the PIGD or TD motor sub-types in patients with PD.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder, manifested by a broad spectrum of motor and non-motor
features [1]. PD may have variable expressions [2] with differences
in the disease profile and progression rate [3]. This clinical
heterogeneity in PD is reflected as clinical subtypes. In fact,
classification according to the disease’s key motor signs into the
Postural Instability Gait Difficulty (PIGD) and tremor dominant
(TD) subtypes is often used to distinguish patients who have very
different clinical symptoms [4].
White matter hyperintensities (WMHs), also referred to as
leukoaraiosis, are commonly observed on brain imaging studies in
older adults, often presenting as signal hyperintensities in MRI
images [5]. These WMHs are associated with and apparently
contribute to balance and gait impairment in aging populations[6–
14]. Given that some of the motor changes that have been
associated with WMHs overlap with features of PD, one can
hypothesize that comorbid WM lesions might contribute to the
clinical symptoms of PD and might explain some of the differences
between PD patients with PIGD symptoms, as compared to TD
patients [15]. WMHs have also been linked with general cognitive
decline in older adults and in normal aging[16–18], and with
impairment in attention, executive functions and processing speed
[19,20]. Interestingly, these cognitive changes are commonly
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e55193observed among patients with PD, even in the early stages of the
disease [21–24].
Among patients with PD, WMHs may contribute to the
development of dementia due, in part, to micro-vascular
changes[25–30]. Even in the absence of dementia, cognitive
deficits are common in patients with PD [31,32], especially among
patients with the PIGD subtype. Patients with vascular parkin-
sonism (VaPD), high level gait disorders (HLGD), and multiple
system atrophy–parkinsonian type (MSA-P) all have balance and
gait disturbances similar to those seen in the PIGD subtype[33–
38]. Moreover, these symptoms are typically accompanied by
impaired executive function [34] and urinary incontinence, two
symptoms that both may reflect frontal lobe dysfunction[39–41].
Studies of leuckoaraiosis severity in PD and its association with
motor impairment show variable results[42–46]. A few reports
suggest that WM lesions are more common in patients with PD
compared to normal elderly individuals [47,48], while other
studies failed to demonstrate this relationship [49,50]. Only two
previous studies directly investigated the role of leuckoaraiosis and
its relationship to the clinical motor phenotypes of PD. Lee et al.
[51]compared 75 TD patients to 54 PIGD and found that WMHs
correlated mildly with bradykinesia and rigidity, but not with
tremor. Recently, Bohnen and colleagues [52] evaluated 25 TD
and 36 PIGD patients; they concluded that WM burden was
higher in the PIGD subtype compared with the TD. Leukoaraiosis
was significantly correlated with posture, postural stability and
with self-report of walking difficulties. Somewhat surprisingly, two
of the main PIGD symptoms, freezing of gait and falls were not
significantly related to WM findings.
The aim of the present study was, therefore, to compare brain
WM burden in PD motor subtypes and to evaluate the associations
between different PIGD-related symptoms and MRI findings.
Materials and Methods
Experimental Design
The study was conducted in the Laboratory for Gait and
Neurodynamics, the Movement Disorders Unit, in the Depart-
ment of Neurology at the Tel Aviv Sourasky Medical Center.
Informed written consent was obtained and the study was
conducted according to the principles expressed in the Declaration
of Helsinki, as approved by the human studies committee of the
Tel Aviv Sourasky Medical Center. In this case-control study,
patients were studied on two separate occasions. The first visit
included a neurological and clinical examination. Several tests
were first performed in the practically-defined ‘‘off’’ medication
state (i.e., at least 12 hours after intake of anti-parkinsonian
medications) to reflect the underlying pathological state. Sub-
sequently, patients took their routine morning medications and the
evaluation continued when the patients reached their ‘‘on’’ state;
tests in this condition reflect typical everyday performance. The
MRI scan was performed on a separate visit that took place within
2 weeks of the clinical exam.
Study Participants
One-hundred and ten patients with idiopathic PD were
recruited from our databases, referrals from specialists at the
outpatient movement disorders unit, and from other affiliated
clinics. Subjects were included if they were diagnosed by
a movement disorders specialist as having idiopathic PD (as
defined by the UK Brain Bank criteria [53]), were between 40 and
85 of age, and were not demented. Subjects were excluded if they
had brain surgery in the past including implanted deep brain
stimulation or had significant co-morbidities likely to affect gait,
e.g., acute illness, orthopedic disease, or history of stroke. In
addition, subjects who could not walk independently in the off
medication cycle, patients with claustrophobia, and patients who
could not undergo MRI testing (e.g., if they had large metal
implants) were excluded.
Classification into PIGD and TD Subtypes
Initially, patients were classified into PIGD, TD or indetermi-
nate groups using the approach proposed in 1990 by Jankovic
et al. [54]. Based on the original Unified Parkinson’s Disease
Rating Scale (UPDRS) [55], we computed a mean tremor score of
9 tremor items (right and left arm tremor by history, lips or chin
tremor, tremor in all 4 limbs, and both arms action or postural
tremor on examination) as well as a mean score of 5 PIGD items
(i.e., falling, freezing, and walking difficulty by history, gait and
postural instability on examination) [56]. Patients were assigned to
the tremor group (TD) if the ratio of the mean tremor score
divided by the mean PIGD score was greater than or equal to 1.5
[57]. Patients were assigned to the PIGD group if this ratio was
equal to or less than 1.0 [58]. When the tremor/PIGD ratio was
more than 1.0 and less than 1.5, patients were classified as
undetermined [59]. In addition, in order to assess correlations
between motor symptoms and WMHs, we used a total TD and
PIGD score rather than the ratio (i.e., the sum of 5 items for the
PIGD score, and the 9 items for the tremor score) [60]. To further
investigate possible associations between WMHs and motor
symptoms, in addition to the total PIGD and TD scores, we also
computed three additional continuous measures derived from the
UPDRS parts II and III: 1) a gait sub-score, 2) a sub-score
comprised from last five measures of the motor part, and 3) the
latter score with the addition of the FOG item.
After performing the ratio based classification, we found that
some of the patients still showed mixed PD symptoms. For
example, patients assigned to the TD group had extensive freezing
of gait and patients from the PIGD group had severe tremor (see
Table 1). Therefore, a stricter criterion was applied on top of the
Jankovic based classification to identify two representative
subtypes, with minimal symptom overlap, referred to here as
predominantly-PIGD (p-PIGD) and predominantly-TD (p-TD).
To compare WMHs in patients with minimal overlapping of
motor symptoms, patients were excluded from the TD group if
they had a PIGD score higher than 3 or a tremor score lower than
4. Similarly, patients were excluded from the PIGD group if their
tremor score was higher than 3 or their PIGD score was lower
than 4.
Clinical Assessment
Parkinsonian symptoms and disease severity were measured
using the new version of the UPDRS introduced by Goetz et al. in
2008 [61]. (Note that this new version of the UPDRS contains all
of the items of the previous version as well as several new items).
Disease duration was defined as time since diagnosis in years. In
addition to observation during the entire clinical testing, the new
Freezing of Gait questionnaire (FOG-Q) was used to assess if the
subject experiences freezing episodes and its severity [62]; in this
test, video segments were shown to the subject and then he or she
was asked to complete a structured questionnaire that character-
izing FOG severity. Subjects walked back and forth along a 35
meter corridor under single and dual task conditions (i.e., while
subtracting serial 3s). Gait speed in the off state was determined by
measuring the average time the subject walked along the middle
10 meters of a the corridor.
The number of falls experienced one year prior to participation
in the study was collected as well via self-report. The cognitive
White Matter and Parkinson’s Disease Sub-Types
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[63] and the Mini Mental State Exam (MMSE) [64]. Since
cerebro-vascular risk factors have been associated with and may
contribute to WM changes [65,66], cerebro-vascular risk factors
were also assessed (i.e., history of high blood pressure, supine and
standing blood pressure, hypercholesterolemia, history of smoking,
history of transient ischemic attacks, diabetes). Further, the total
number of risk factors was computed as a cerebro-vascular risk
index. Deep WMHs have also been associated with altered
functioning of the frontostriatal circuits and depressive symptoms
in both the general elderly and patients with PD [67,68] and
could, perhaps, be a mediator of gait disturbances in PD. To
address this possibility, we also assessed depressive symptoms using
the Geriatric Depression Scale [69].
MRI Acquisition
Acquisition was performed in the ‘‘on’’ medication state using
a GE 3T imaging system. All MRI analyses were performed in
a blinded manner without knowledge of the subject’s age, gender,
UPDRS scores, or group assignment. A fluid attenuated inversion
recovery (FLAIR) sequence was used for the semi-quantitative
visual rating of WMHs and for the automated methods using the
following parameters: TR=6,200 milliseconds, TE=200 milli-
seconds, flip angle=90, slice thickness=1.2 mm, ma-
trix=2566256, FOV=30.7630.7 cm
2.
WMHs were first visually examined and evaluated by a blinded
rater using the visual rating of signal hyperintensities, as developed
by Scheltens and colleagues [70]. Scheltens’ method quantifies the
number, size and location of WM lesions. This scale has good
inter- and intra-rater agreement [71] and has been validated in
several previous studies[72–74]. The Schelten rating scale provides
summary scores in a semi-quantitative way: periventricular
hyperintensities (PVH scored as 0–6, where 0 indicates no
hyperintensities) and lobar white matter (WMH scored as 0–24).
Operationally, PVH were identified as continuous confluent areas
of high signal intensity adjacent to anterior or posterior horns of
the lateral ventricles (‘‘caps’’) and along the lateral ventricles
(‘‘bands’’). WMH, located in the deep and subcortical white
matter, were separately rated according to anatomical location
(i.e., the frontal, parietal, temporal, and occipital regions) [75].
The manual segmentation of the four lobes was performed using
an axial view of a representative volume segmentation for manual
tracing of the lobes [76].
Given the inconsistency among previous reports on WMHs in
PD[77–80], we also used two automated methods to further
investigate possible white matter differences between the PIGD
and TD groups. One automated method was suggested and
validated recently by Smart and colleagues [81]. In brief, the Flair
images were first spatially normalized to the T1 weighted MNI
(Montreal Neurological Institute) template using SPM (Wellcome
Department of Imaging Neuroscience Group, London, UK;
http://www.fil.ion.ucl.ac.uk/spm). Following this normalization,
images were automatically segmented, based on prior probability
maps of the relative distribution of tissue types, into grey matter
(GM), white matter (WM) and cerebrospinal fluid (CSF), as
implemented in the VBM toolbox in SPM5. WMHs were selected
by labeling voxels with intensities greater than 1.45 times the mean
WM voxel intensity. Then, the WMHs score was calculated as the
Table 1. Demographics and basic disease characteristics.
Measure All Patients (n=110)
PIGD Patients
(n=62)
TD Patients
(n=42)
Undetermined
(n=6)
P-value
(PIGD vs. TD)
Age (yrs) 65.1369.23 64.8067.96 65.88611.00 63.3368.98 0.587
Gender (% male) 75.5% 74.2% 81.0% 50.0% 0.242
Education (yrs) 15.4763.74 15.8563.98 15.1763.38 13.6763.39 0.361
Weight (kg) 77.54612.40 78.11613.65 77.58612.4 70.95610.67 0.965
Height (cm) 169.368.7 169.068.4 170.768.7 164.3368.9 0.258
Body-mass-index (kg/m2) 26.8563.52 27.1463.72 26.4163.24 26.2363.20 0.322
Disease duration (yrs) 5.5863.52 5.5963.8 5.3862.98 7.3364.33 0.691
UPDRS motor score ‘‘off’’ 40.45613.03 38.11611.30 42.79614.16 48.33617.69 0.065
UPDRS motor score ‘‘on’’ 33.85611.96 32.65611.13 35.79613.32 32.83610.14 0.195
Total UPDRS score ‘‘on’’ 60.69619.61 60.19617.62 60.50623.11 67.16612.76 0.942
Hoehn & Yahr stage ‘‘off’’ 2.5860.69 2.8360.75 2.2460.43 2.3360.41 0.001
PIGD score 4.6263.18 6.1863.27 2.4361.42 3.8361.32 0.001
Tremor score 7.0565.85 2.9562.64 12.8664.31 8.6763.61 0.001
Age of motor symptom
onset
59.5469.46 59.1668.55 60.59610.80 56.0868.75 0.474
Montreal Cognitive
Assessment
25.3263.14 25.1963.28 25.6263.06 24.5062.43 0.506
Mini Mental State Exam 28.7261.7 28.4861.9 29.1261.1 28.3361.0 0.038
Geriatric Depression Scale 4.0763.35 3.8962.93 3.8363.67 7.6763.56 0.934
Pull test ‘‘Off’’ 1.1561.25 1.5661.28 0.5260.86 1.1761.47 0.001
Freezing of Gait (FOG-Q) 4.2967.83 6.2768.71 1.3865.32 4.6768.16 0.001
Number of falls (year prior
to the study)
1.9167.63 3.22610.11 0.3160.68 0.2160.45 0.033
doi:10.1371/journal.pone.0055193.t001
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this method, the term WMHref-total will be used.
The second automatic method followed the approach used by
Bohnen et al. [82]. The mean intensity of cerebellar white matter
voxels on magnetic resonance FLAIR images served as a reference.
WMHs were selected by labeling voxels with intensity greater than
1.65 times the mean voxel intensity in the cerebellum. The
cerebellum is used as a reference in this method based on the
clinical observation that this region is generally spared from age-
associated WM changes. For this method, we use the term
WMHref-cereb.
Statistical Analysis
The PIGD and the TD groups were compared using Student’s
t-test for continuous variables (or its non-parametric equivalent)
and Chi-square tests were used for categorical variables (e.g.,
gender) to see if the groups were similar with respect to
background measures, demographics, and WM scoring. Associa-
tions among the different measures were tested using correlation
analyses (Pearson or Spearman, as appropriate) and using partial
correlations adjusting for potential covariates (e.g., age). All
statistical analyses were two-sided and conducted using the
Statistical Package for Social Sciences (Version 19 for Windows;
SPSS Inc., Chicago, IL, U.S.A.). Average values are reported as
mean6standard deviation. Significance was set at the 0.05 level
for all analyses.
Results
Demographics and Clinical Findings
110 patients with PD participated in this study. Basic
characteristics and demographics of all the subjects and the PIGD
and TD subtypes are summarized in Table 1. Based on the
categorization proposed by Jankovic et al [83], 42 patients (38.2%)
were classified as TD, 62 patients (56.4%) were classified as PIGD,
and six patients (5.5%) were classified as undetermined. Among all
subjects, the PIGD score ranged from 0–14, while the Tremor
score ranged from 0–23. As indicated in Table 1, the PIGD and
TD subtypes were similar with respect to basic demographics and
disease characteristics. As expected, significant group differences in
motor symptoms related to PIGD and TD were observed. In
general, the subjects were non-demented, as indicated by relatively
high scores on the MMSE and MoCA. Interestingly, 48 of the
subjects had a MoCA score of 25 or below (with similar means and
distributions in both groups) suggesting that many of the subjects
had some degree of cognitive decline.
Mean gait speed among all subjects in the off state was
1.1160.21 m/sec, ranging from 0.49–1.58 m/sec. The mean gait
speed in the dual task condition was 0.9860.26 m/sec, ranging
from 0.26–1.52 m/sec. Gait speed was significantly lower
(p=0.049) in the PIGD group (1.0860.21 m/sec), compared to
the TD group (1.1760.20 m/sec). A marginal effect was found in
the dual task condition; walking speed tended (p=0.088) to be
lower in the PIGD patients (0.9460.28 m/sec), compared to the
TD patients (1.0460.21 m/sec). Five subjects from the PIGD
group had more than 3 falls in the year prior to the study. In
contrast, none of the TD patients had this many falls. In general,
patients from the PIGD subtype had significantly more falls than
patients from the TD group (Table 1).
MRI Findings
From among the 110 patients, MRI data was not fully available
for 6 subjects. Four patients were unable to complete the MRI
scan due to intolerance to noise or inability to lie still while prone
in the magnet. In addition, the first two patients who participated
in this protocol did not have the FLAIR sequence needed for the
visual rating. Before starting the project, we were concerned that
severe tremor might disturb the MRI procedure and impact on the
quality of the images. However, this was not the case; for all
participants, the quality of the MRI signals was not affected by
tremor or dyskinesias. Thus, complete MRI data were obtained in
104 patients.
WMHs results based on Scheltens’ visual rating scale are
summarized in Table 2. As indicated, there were no significant
PIGD vs. TD group differences in the mean scores or in the
percent of subjects with lesions, overall or in specific brain regions.
Examples of periventricular WMHs in patients with PIGD and
TD are shown in Figure 1. This figure illustrates how the PIGD-
TD grouping can be independent of WMHs as scored using
Scheltens’ method.
As expected, across almost all brain regions, significant mild to
moderate correlations between WMHs and age were found.
Pearson’s correlation coefficients ranged from r=0.26 to r=0.41.
However, no correlations were found between WMHs and the
PIGD scores (Figure 2), TD scores, or disease duration (see
Table 3). The absence of correlations between WMHs and PIGD
and TD scores persisted in partial correlations that adjusted for
age and/or disease duration; correlations between WMHs and the
PIGD score (p.0.437) and with the TD score (p.0.179) were not
significant. Similarly, correlations between WMHs and the
objective continuous measure from the last five items of part 3
of the UPDRS (with or without including the FOG item and the
gait sub-scores) were mild (r,0.25) and were no longer significant
after adjusting for age.
We applied Scheltens’ approach specifically to the basal ganglia,
the hallmark of PD and the thalamus, one of the likely sources of
tremor in PD [84,85]. Only two patients (one from the PIGD
group and one undetermined) had WM lesions in the thalamus,
while two other patients had lesions in the basal ganglia.
According to this method, WM lesions were not common in the
basal ganglia and the thalamus, and did not differ in PD subtypes.
Using the automated method with the cerebellum as a reference
(WMHref-cereb), the mean number of voxels with WMHs was
similar in the two groups (p=0.413); the number of voxels with
WMHs was 12143.4620472.8 in the PIGD group and
16004.5625172.2 in the TD group. In addition, the mean
WMHs ratio was 0.024460.0382 in the PIGD group and
0.024060.0047 in the TD group (p=0.678). Using the other
automated method, WMHref-total, WMHs were also not larger in
the PIGD group. In fact, this method suggests that there was
a higher WMH burden in the TD group compared to the PIGD
group (number of WMH voxels: PIGD 4117.0864818.02; TD:
7033.2666963.99; p=0.027). Similarly, the WMH ratio was
significantly higher (p=0.027) in the TD group (0.013560.0132),
compared to the PIGD group (0.007960.0091), indicating greater
WMHs in the TD group, according to the WMHref-total
approach. Similar results were obtained for the two automated
methods if the results were log transformed.
We further calculated quartiles of the WMHs variables and
compared the 1
st quartile (fewest WMHs) to the 4
th quartile (most
WMHs). This analysis, again, did not detect differences between
the subtypes. For the WMHref-cereb method, there was no
association between the 1
st and 4
th quartile and PIGD grouping
(p=0.99). For example, among the subjects with the most WMHs,
45% were in the TD group; similarly, among the subjects with the
least amount of WMH, 45% were from the TD group. A
comparison of the quartiles based on the second automated
method (WMHref-total) also revealed no significant association
White Matter and Parkinson’s Disease Sub-Types
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same analysis using the semi-quantitative visual rating scores,
again, no significant association with PIGD and TD grouping was
found (p=0.166).
Figure 1. An example of periventricular WMHs in two patients with the PIGD subtype and two patients with the TD subtype. As
shown, a subject with PIGD had a low score on the Scheltens scale, while another had a relatively high score (5 out of max. possible 6). Similarly, one
patient in the TD group had a low score, while another had a relatively high score. These examples are consistent with the lack of an association
between the Scheltens’ scoring and PIGD and TD subtypes that was seen in general.
doi:10.1371/journal.pone.0055193.g001
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subjects into representative motor subtypes, 29 (26.4%) patients
were included in the predominantly-PIGD subtype (p-PIGD) and
31 (28.2%) patients were assigned to the predominantly-TD (p-
TD) subtype; (mean age: 64.967.7 vs. 64.6611.6 yrs, respectively;
p=0.900). Age of motor symptom onset (p=0.968) and disease
duration (p=0.700) were also similar in both of these groups. Here
as well, no significant differences were observed for all WMHs
measures. For example, using the visual scoring method, the total
score of periventricular hyperintensities was 1.3161.82 in the p-
PIGD group and 1.3161.61 in the p-TD (p=0.993). Using the
automated method WMHref-cereb, the WMH ratios were
0.024060.0031 in the PIGD group and 0.023860.0048 in the
TD group (p=0.901).
Associations between WMHs, Freezing of Gait and Falls
The number of falls in the previous year was moderately
correlated with the PIGD score (r=0.471, p,0.001), but not with
the TD score. In addition, a mild correlation was found between
the number of falls and the freezing of gait questionnaire score
(FOG-Q); (r=0.309, p=0.001). However, no significant correla-
tion was found between number of falls and WMHs using all three
methods (p.0.471). The FOG-Q score was highly correlated with
the PIGD score (r=0.770, p,0.001), but not with the TD score.
The FOG-Q score was not correlated with WMHs using the
Scheltens’ score (p.0.287) or with WMHref-cereb scores
(p.0.710). Surprisingly, patients with more FOG episodes (i.e.,
higher FOG-Q scores) tended to have less WMHs using the
WMHref-total method (r=20.172, p=0.093).
Association between WMHs and Cerebro-vascular Risk
Factors
Table 4 summarizes the cerebro-vascular risk factors among the
two groups. Overall, no significant differences were found between
the groups (except that more patients in the TD group tended to
have diabetes). Moreover, the cerebro-vascular risk index (based
on the presence or absence of any risk factor) suggests that, in
general, risk factors were similar in the two groups.
Discussion
We hypothesized that greater WM changes would be observed
in the PIGD-subtype compared to the TD subtype. The PIGD
and TD groups differed with respect to many motor symptoms, as
expected. Falls were more common in the patients with PIGD and
they also had worse postural control. We could not, however, find
any evidence to support our hypothesis. The three different
methods that were applied for detecting WMHs showed no
increase in WMHs among the PIGD (or even among the p-PIGD)
patients, compared to patients with TD. Some visual rating scales
may suffer from ceiling effects [72,86]. Nonetheless, we did not
observe this problem and the results from the two automated
methods also were not associated with PIGD symptoms. In
addition, very mild correlations between WMHs and UPDRS
derived measures were observed, however, these correlations were
not observed after adjusting for age. Thus, while the association
between WMHs, gait, mobility, impaired balance, falls and
cognitive deficits are well established in otherwise healthy older
adults [87,88], the present findings do not support this relationship
among patients with PD.
In contrast to our findings, Bohnen et al. [89] reported that
WMHs burden was significantly related to the PIGD motor
phenotype. However, their analysis did not adjust for age, a factor
Table 2. Visual rating of White Matter Hyperintensities according to Schelten et al.
Group Comparisons
Outcome Measure
PIGD (N=59) (Mean6SD
or n, %)
TD (N=40)
(Mean6SD or n, %) P-Value PIGD vs. TD
Deep WMHs Frontal With lesions, n (%) 39 (66.1%) 27 (67.3%) 0.885
Score, mean6 SD 1.8361.77 1.9761.95 0.713
Parietal With lesions, n (%) 27 (45.8%) 18 (45.2%) 0.940
Score, mean6 SD 1.2261.72 1.0561.37 0.613
Temporal With lesions, n (%) 10 (16.9%) 6 (15.4%) 0.796
Score, mean6 SD 0.2160.52 0.2760.73 0.624
Occipital With lesions, n (%) 10 (16.9%) 11 (27.2%) 0.208
Score, mean6 SD 0.4361.05 0.6561.38 0.385
Sum (possible range 0–24) Score, mean6 SD 3.6663.96 3.9563.97 0.732
Periventricular
Hyperintensities
Frontal With lesions, n (%) 15 (25.4%) 14 (35.9%) 0.352
Score, mean6 SD 0.3360.63 0.4360.65 0.446
Occipital With lesions, n (%) 16 (27.1%) 11 (28.2%) 0.967
Score, mean6 SD 0.3860.68 0.4160.73 0.870
Bands With lesions, n (%) 27 (45.8%) 19 (48.7%) 0.865
Score, mean6 SD 0.6060.75 0.6660.78 0.707
Sum (possible range 0–6) Score, mean6 SD 1.3161.73 1.561.69 0.606
Total sum (DWM+PVH) Score, mean6 SD 4.9765.39 5.4565.40 0.678
Deep White Matter Hyperintensities (DWM); Periventricular Hyperintensities (PVH).
doi:10.1371/journal.pone.0055193.t002
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classification method for dividing the patients into subtypes in that
study appears to be slightly different from that originally proposed
by Jankovic et al [92]. Moreover, while leukoaraiosis was
significantly correlated with posture and postural stability by
examination and with walking by history, it was only marginally
correlated with freezing of gait and no correlation was found with
falls in the study by Bohnen et al. Using conventional MRI
obtained with a 1.5-T system, Lee et al. [93] observed greater
WMHs in the PIGD patients compared to TD, graded according
Figure 2. A scatter plot showing the absence of an association between the PIGD score and the total (periventricular and deep)
WMHs scores, as determined using the Scheltens methods. WMHs were not correlated with PIGD symptoms.
doi:10.1371/journal.pone.0055193.g002
Table 3. Correlations between Schelten’s scoring of WMHs and PIGD and TD symptom.
Outcome Measure Age Disease Duration PIGD Score TD Score
Deep White Matter Hyperintensities Frontal r=0.40* (0.001) r=0.007 (0.941) r=0.12 (0.217) r=0.06 (0.558)
Parietal r=0.32 (0.001) r=0.20 (0.867) r=0.16 (0.109) r=0.01 (0.923)
Temporal r=0.03 (0.781) r=0.03 (0.780) r=20.04 (0.685) r=0.03 (0.760)
Occipital r=0.23 (0.021) r=0.03 (0.735) r=0.04 (0.699) r=0.12 (0.239)
Sum DWM r=0.38 (0.001) r=0.03 (0.731) r=0.12 (0.223) r=0.06 (0.531)
Periventricular Hyperintensities Frontal r=0.39 (0.001) r=0.04 (0.698) r=0.05 (0.614) r=0.16 (0.102)
Occipital r=0.26 (0.008) r=0.05 (0.630) r=0.12 (0.249) r=0.07 (0.486)
Bands r=0.33 (0.001) r=0.17 (0.082) r=0.16 (0.110) r=0.16 (0.103)
Sum PV r=0.41 (0.001) r=0.13 (0.180) r=0.13 (0.196) r=0.17 (0.082)
Total sum DWM & PV r=0.40 (0.001) r=0.07 (0.457) r=0.12 (0.214) r=0.10 (0.337)
*Entries are Pearson’s correlation coefficient and the associated p-value. Deep White Matter Hyperintensities (DWM); Periventricular Hyperintensities (PVH).
doi:10.1371/journal.pone.0055193.t003
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visual rating scale. These methodological differences may explain
the differences between our findings and those of Bohnen et al.
and Lee et al., however, future studies are needed to resolve these
somewhat puzzling and conflicting results.
In a recent systemic review about WMHs, physical functioning
and falls in older adults, Zheng at al. [94] concluded that impaired
mobility and an increased fall risk are only evident in people who
have the most severe degree of WMHs. We tested this possibility
when we examined the relationship between PIGD grouping and
WMH quartiles. Even after stratifying the WMHs variables into
quartiles to compare only patients with least and most severe
degrees of WM changes, we failed to find an association between
WMHs and PIGD symptoms. These findings also suggest that the
relationships observed in older adults are not found in patients
with PD, even among those with relatively severe leukoaraiosis.
Perhaps impairments due to dopamine loss make the WMHs less
relevant among patients with PD.
The mechanisms linking WMHs and motor function in older
adults are not fully understood. However, reports on the
association of frontal and periventricular age-related WM changes
with falls support the hypothesis that interruption of frontal
subcortical motor circuits lead to balance disturbances and hence
to an increased risk for falls [95]. A recent review of studies among
older adults supports the idea that a high WM burden is associated
with gait disorders and observed that the largest WMH fractions
were found in the frontal lobe, the centrum semiovale, the
posterior limb of internal capsule, the genu and the splenium of
corpus callosum [96]. In the present study, two thirds of the
subjects had WMHs in frontal regions, while lesions were less
common in other regions (recall Table 3). Still, there was no
association between lesion location and gait disturbances, further
suggesting that the relationship between WMHs and gait and falls
in patients with PD is different from that observed in older adults
who do not have PD.
If WMHs do not play a major role in the PIGD clinical
phenotype, other pathological processes must explain the existence
of the motor subtypes in PD. One possible explanation for the
differences between PIGD and TD might be due to gray matter
(GM) alterations. Tremor has been related to GM atrophy in the
thalamus [97] and in the cerebellum [98]. Additionally, in a recent
study by Kostic et al. [99], PD patients with freezing of gait
showed a distributed pattern of GM atrophy compared to controls
and compared to PD patients without FOG, reinforcing the
possible association between axial symptoms and GM frontal and
parietal atrophy. Indirectly, genetics might also contribute to the
different motor symptoms, although there have been conflicting
reports in the literature regarding the link between mutations and
the clinical subtypes [100,101]
, [102]. A third possibility is that the
group differences may be related to more subtle changes in WM.
In the present study, our focus was on leukoaraiosis; perhaps more
advanced technology (e.g., 7 Tesla MRI) or imaging techniques
that examine more subtle changes in WM organization and the
alignment of fibers (e.g., diffusion tensor imaging, DTI) [103,104]
might provide some of the explanation. Another possibility is that
the anti-parkinsonian medications that are aimed at treating motor
symptoms in PD may alter the expression of WMHs. Finally, it is
possible that distinct patterns of neurodegeneration contribute to
the different clinical features. One can speculate that pathology at
the level of the brainstem nuclei could affect cerebellar outflow as
well as the degree of involvement of the pedunculo-pontine
nucleus (PPN) or the nucleus Basalis of Meinert. As a result,
differences between a PIGD course or TD course could be the
result of different functional connectivity between those centers
causing differentiation at the level of brain networks. These
questions can only be answered by large scale clinical-pathological
studies that are augmented by functional imaging methods.
Strengths, Limitations and Future Directions
Strengths of the present study include the relatively large sample
and the use of three different methods for evaluation and analysis
of WMHs, all performed while blinded to PIGD and TD group
assignments. One limitation of this study is its cross-sectional
nature which precludes the investigation of changes over time. In
the future, prospective documentation of natural history of PD and
its association (or lack thereof) with WMHs, disease progression,
changes in the clinical phenotypes, vascular risk factors, and
markers of inflammation may shed additional light on the
pathogenesis of the PIGD motor subtype. In addition, it would
be helpful to compare each of the subtypes to an age-matched
control group in the future. Another limitation is the exclusion of
subjects with significant gait impairment in the off medication state
and patients with mild to moderate dementia. These criteria might
have biased the study and may have lead to the negative
association. Nonetheless, we note that there was a wide range in
both motor and cognitive abilities (recall Table 1).
Table 4. Cerebro-vascular risk factors.
Group Comparisons
Outcome Measure All Patients* PIGD Patients TD Patients P-Value PIGD vs. TD
Diabetes 9.6% 5.0% 17.5% 0.093
High Blood Pressure (by history) 49.5% 45.9% 56.1% 0.546
Supine BP (Systolic) (mmHg) 125.61615.91 126.95616.57 124.64615.18 0.490
Supine BP (Diastolic) (mmHg) 74.74610.29 75.9169.47 73.33611.27 0.228
Years of Smoking 8.57614.63 10.27615.56 6.31613.75 0.213
Hyper-cholestermia 39.3% 45.9% 29.3% 0.241
Vascular Risk Index (possible range: 0–4) 23.1%
31.5%
29.6%
15.7%
17.7%
35.5%
30.6%
16.1%
30.8%
23.1%
28.2%
17.9%
0.595
*Entries are % of subjects or mean6SD.
doi:10.1371/journal.pone.0055193.t004
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To improve a clinician’s ability to tailor therapy to the
individual patient, it is important to understand why a subset of
patients with PD primarily have PIGD symptoms, while others
experience mainly tremor with relatively little gait and postural
difficulties. In contrast to our expectations, the present findings
suggest that cererbro-vascular findings and white matter structural
changes are likely not the cause of these differences. Future studies
should, therefore, focus their efforts on other possible explanations.
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